Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults

• Main Authors: Susan B. Manoff (Author), Michele Sausser (Author), Amy Falk Russell (Author), Jason Martin (Author), David Radley (Author), Donna Hyatt (Author), Christine C. Roberts (Author), Jason Lickliter (Author), Janakan Krishnarajah (Author), Andrew Bett (Author), Sheri Dubey (Author), Tyler Finn (Author), Beth-Ann Coller (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

There is an unmet medical need for vaccines to prevent dengue. V180 is an investigational recombinant subunit vaccine that consists of truncated dengue envelope proteins (DEN-80E) for all 4 serotypes. Three dosage levels of the tetravalent DEN-80E antigens were assessed in a randomized, placebo-cont...